176 related articles for article (PubMed ID: 26048791)
1. Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist series.
Han S; Narayanan S; Kim SH; Calderon I; Zhu X; Kawasaki A; Yue D; Lehmann J; Wong A; Buzard DJ; Semple G; Carroll C; Chu ZL; Al-Sharmma H; Shu HH; Tung SF; Unett DJ; Behan DP; Yoon WH; Morgan M; Usmani KA; Chen C; Sadeque A; Leonard JN; Jones RM
Bioorg Med Chem Lett; 2015 Aug; 25(15):3034-8. PubMed ID: 26048791
[TBL] [Abstract][Full Text] [Related]
2. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
[TBL] [Abstract][Full Text] [Related]
3. Optimization of a novel series of potent and orally bioavailable GPR119 agonists.
Koshizawa T; Morimoto T; Watanabe G; Watanabe T; Yamasaki N; Sawada Y; Fukuda T; Okuda A; Shibuya K; Ohgiya T
Bioorg Med Chem Lett; 2017 Aug; 27(15):3249-3253. PubMed ID: 28648463
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel 7-azaspiro[3.5]nonane derivatives as GPR119 agonists.
Matsuda D; Kawamura M; Kobashi Y; Shiozawa F; Suga Y; Fusegi K; Nishimoto S; Kimura K; Miyoshi M; Takayama N; Kakinuma H; Ohtake N
Bioorg Med Chem; 2018 May; 26(8):1832-1847. PubMed ID: 29486951
[TBL] [Abstract][Full Text] [Related]
5. Discovery of structurally novel, potent and orally efficacious GPR119 agonists.
Alper P; Azimioara M; Cow C; Mutnick D; Nikulin V; Michellys PY; Wang Z; Reding E; Paliotti M; Li J; Bao D; Zoll J; Kim Y; Zimmerman M; Groessel T; Tuntland T; Joseph SB; McNamara P; Seidel HM; Epple R
Bioorg Med Chem Lett; 2014 May; 24(10):2383-7. PubMed ID: 24751443
[TBL] [Abstract][Full Text] [Related]
6. Optimization of oxadiazole derivatives with a spirocyclic cyclohexane structure as novel GPR119 agonists.
Harada K; Mizukami J; Watanabe T; Mori G; Ubukata M; Suwa K; Fukuda S; Negoro T; Sato M; Inaba T
Bioorg Med Chem Lett; 2019 Aug; 29(16):2100-2106. PubMed ID: 31288965
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile.
Semple G; Lehmann J; Wong A; Ren A; Bruce M; Shin YJ; Sage CR; Morgan M; Chen WC; Sebring K; Chu ZL; Leonard JN; Al-Shamma H; Grottick AJ; Du F; Liang Y; Demarest K; Jones RM
Bioorg Med Chem Lett; 2012 Feb; 22(4):1750-5. PubMed ID: 22264481
[TBL] [Abstract][Full Text] [Related]
8. Discovery, optimisation and in vivo evaluation of novel GPR119 agonists.
Brocklehurst KJ; Broo A; Butlin RJ; Brown HS; Clarke DS; Davidsson Ö; Goldberg K; Groombridge SD; Kelly EE; Leach A; McKerrecher D; O'Donnell C; Poucher S; Schofield P; Scott JS; Teague J; Westgate L; Wood MJ
Bioorg Med Chem Lett; 2011 Dec; 21(24):7310-6. PubMed ID: 22061639
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic potential of GPR119 agonists for type 2 diabetes.
Ohishi T; Yoshida S
Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of novel and potent GPR119 agonists with a spirocyclic structure.
Harada K; Mizukami J; Kadowaki S; Matsuda I; Watanabe T; Oe Y; Kodama Y; Aoki K; Suwa K; Fukuda S; Yata S; Inaba T
Bioorg Med Chem Lett; 2018 Apr; 28(7):1228-1233. PubMed ID: 29519733
[TBL] [Abstract][Full Text] [Related]
11. GPR119 agonists for the treatment of type 2 diabetes.
Jones RM; Leonard JN; Buzard DJ; Lehmann J
Expert Opin Ther Pat; 2009 Oct; 19(10):1339-59. PubMed ID: 19780700
[TBL] [Abstract][Full Text] [Related]
12. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119.
Semple G; Fioravanti B; Pereira G; Calderon I; Uy J; Choi K; Xiong Y; Ren A; Morgan M; Dave V; Thomsen W; Unett DJ; Xing C; Bossie S; Carroll C; Chu ZL; Grottick AJ; Hauser EK; Leonard J; Jones RM
J Med Chem; 2008 Sep; 51(17):5172-5. PubMed ID: 18698756
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119.
Wacker DA; Wang Y; Broekema M; Rossi K; O'Connor S; Hong Z; Wu G; Malmstrom SE; Hung CP; LaMarre L; Chimalakonda A; Zhang L; Xin L; Cai H; Chu C; Boehm S; Zalaznick J; Ponticiello R; Sereda L; Han SP; Zebo R; Zinker B; Luk CE; Wong R; Everlof G; Li YX; Wu CK; Lee M; Griffen S; Miller KJ; Krupinski J; Robl JA
J Med Chem; 2014 Sep; 57(18):7499-508. PubMed ID: 25208139
[TBL] [Abstract][Full Text] [Related]
14. Lead generation and optimization of novel GPR119 agonists with a spirocyclic cyclohexane structure.
Harada K; Mizukami J; Watanabe T; Mori G; Ubukata M; Suwa K; Fukuda S; Negoro T; Sato M; Inaba T
Bioorg Med Chem Lett; 2019 Feb; 29(3):373-379. PubMed ID: 30587450
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes.
Xia Y; Chackalamannil S; Greenlee WJ; Jayne C; Neustadt B; Stamford A; Vaccaro H; Xu XL; Baker H; O'Neill K; Woods M; Hawes B; Kowalski T
Bioorg Med Chem Lett; 2011 Jun; 21(11):3290-6. PubMed ID: 21536438
[TBL] [Abstract][Full Text] [Related]
16. Design and biological evaluation of tetrahydropyridine derivatives as novel human GPR119 agonists.
Zuo Z; Chen M; Shao X; Qian X; Liu X; Zhou X; Xiang J; Deng P; Li Y; Jie H; Liu C; Cen X; Xie Y; Zhao Y
Bioorg Med Chem Lett; 2020 Feb; 30(4):126855. PubMed ID: 31898998
[TBL] [Abstract][Full Text] [Related]
17. AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes.
Yoshida S; Tanaka H; Oshima H; Yamazaki T; Yonetoku Y; Ohishi T; Matsui T; Shibasaki M
Biochem Biophys Res Commun; 2010 Oct; 400(4):745-51. PubMed ID: 20816753
[TBL] [Abstract][Full Text] [Related]
18. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice.
Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M
Biochem Biophys Res Commun; 2010 Nov; 402(2):280-5. PubMed ID: 20937249
[TBL] [Abstract][Full Text] [Related]
19. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
Bazydlo-Guzenda K; Buda P; Matloka M; Mach M; Stelmach F; Dzida R; Smuga D; Hucz-Kalitowska J; Teska-Kaminska M; Vialichka V; Dubiel K; Kaminska B; Wieczorek M; Pieczykolan J
Mol Pharmacol; 2021 Oct; 100(4):335-347. PubMed ID: 34349026
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available G protein-coupled receptor 119 agonists.
Katamreddy SR; Carpenter AJ; Ammala CE; Boros EE; Brashear RL; Briscoe CP; Bullard SR; Caldwell RD; Conlee CR; Croom DK; Hart SM; Heyer DO; Johnson PR; Kashatus JA; Minick DJ; Peckham GE; Ross SA; Roller SG; Samano VA; Sauls HR; Tadepalli SM; Thompson JB; Xu Y; Way JM
J Med Chem; 2012 Dec; 55(24):10972-94. PubMed ID: 23214471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
